ATAI Beckley

formerly AtaiBeckley Inc.Acquired

AtaiBeckley | Creating breakthroughs in mental health

New York, United States · Founded 2025 · $357.1M raised

Headquarters
New York, New York
Employees
51–200
Founded
2025
Business Model
B2B
Total Funding
$357.1M
Last Round
$160.0M Series DMar 2021
Rounds
5
Acquisition Date
Nov 2025

Totals include recorded grants and other qualifying funding, not just equity. What counts toward funding.

About

AtaiBeckley Inc. is a clinical-stage biotechnology company formed in November 2025 through the merger of atai Life Sciences and Beckley Psytech, and publicly traded on Nasdaq (ATAI). The company is focused on developing rapid-acting, durable, and convenient treatments for mental health disorders where current options are severely limited, with a pipeline centered on psychedelic-derived compounds including mebufotenin (5-MeO-DMT) for treatment-resistant depression, DMT for treatment-resistant depression, and (R)-MDMA for social anxiety disorder. Headquartered in New York City and redomiciled to the United States in December 2025, AtaiBeckley combines deep expertise in psychedelic medicine, drug development, and commercialization to pursue large-scale patient impact in mental health.

Summary

ATAI Beckley is a Biotech company based in New York, United States, founded in 2025. It has raised $357.1M in total across 5 rounds, most recently a $160.0M Series D round in Mar 2021. Investors include Eli Lilly, ATAI Life Sciences and FJ Labs.

Tech & App Stack

2 technologies & apps tracked

Every product and vendor across these categories, with where each signal came from.

Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.

Funding & Exit History

AcquisitionJul 2026

Sign up to see all 9 events

Funding: Seed through Series D. Amounts, valuations, and investors where available.

Investors

Similar Companies

Pharmaceutical Product Development, Inc. (PPD)Acquired

Global contract research organization providing comprehensive drug development and laboratory ser...

Wilmington, United States10001+Biotech, Healthcare
Private EquityTotal funding$3.9BJan 2019
Warner ChilcottAcquired

Specialty pharmaceutical company

Rockaway, United States1001–5000Biotech, Healthcare
Private EquityTotal funding$3.0BJan 2004
Altos Labs

Altos Labs combines academic science and industry development to create medicines that restore ce...

San Francisco, United States501–1000Life Sciences, Biotech
Series ATotal funding$3.0BJan 2022
Syneos HealthAcquired

Integrated biopharmaceutical solutions company

Burlington, United States10001+Biotech, Healthcare
Private EquityTotal funding$3.0BMay 2017
BeiGeneIPO

BeOne Medicines develops transformative oncology medicines through rigorous science, an accelerat...

Cambridge, United States10001+Biotech, Oncology
Corporate RoundTotal funding$2.8BJan 2020
BridgeBioIPO

BridgeBio develops treatments for genetic conditions through autonomous condition-focused teams s...

San Francisco Bay Area, United States201–500Biotech, Healthcare
Growth EquityTotal funding$2.7BJul 2026

Your company? Embed this profile

Add the live badge to your site — it stays current as your funding data updates.

ATAI Beckley on Indexed.vc
<a href="https://indexed.vc/companies/atai-beckley"><img src="https://indexed.vc/api/badge/company/atai-beckley" alt="ATAI Beckley on Indexed.vc" width="260" height="76" /></a>